Tag: Motley Fool

  • Afterpay (ASX:APT) share price up 4% in today’s trading

    asx shares higher

    The Afterpay Ltd (ASX: APT) share price continues to climb today, up 4.44% to $104.96 at the time of writing. This is despite differing views on the buy now, pay later (BNPL) leader from two major banks over the past week, and comes after a 3.9% rise across last week.

    Why the disagreement over Afterpay?

    Westpac Banking Corp (ASX: WBC) CEO Peter King has defended the decision to provide Afterpay with access to the Westpac’s deposit and transaction accounts. Some analysts had disagreed with the move, believing the bank would lose its relationship with younger customers. But Mr King told shareholders at the Westpac AGM recently:

    When we look at banking and how it is provided, we think it is fundamentally changing. Other banks are seeking to provide infrastructure to fintechs and this is a market Westpac wants to be in.

    Westpac’s banking as a service platform will allow Afterpay to provide branded saving and transaction accounts. It will then be able to link these to customers’ existing Afterpay accounts. This provides Afterpay’s customers with an alternative to traditional banking, and gives Afterpay a scalable platform to expand globally. When this was announced the Afterpay share price spiked 7%.

    Currently, National Australia Bank Ltd (ASX: NAB) is leading the banks in terms of warehouse finance arrangements, or debt funding for fintech companies. 

    However, Australia and New Zealand Banking GrpLtd (ASX: ANZ) has a different view. In an interview with Ticky Fullerton of Sky News, outgoing chairman David Gonski declared his skepticism of the BNPL business. ANZ CEO Mr Shayne Elliot went further, saying that Afterpay’s 3.5 million customers were generally not high savers motivated to buy their own homes, and therefore were not a good fit with the bank.

    Forces driving the Afterpay share price

    Despite these differing viewpoints, Afterpay continues to display strong growth metrics in every quarterly update. The recent first quarter FY21 update saw sales grow by 9% than the record underlying sales of Q4FY20. Moreover, the company’s active users has increased to 11.2 million, with the US reaching over 6.5 million. 

    Furthermore, 45% of like for like sales growth is driven by millennials. Gen X and Gen Z then form 25% and 24% respectively. Lastly, the company’s number of active merchants has increased to 63.8 k. An increase of 70% year on year. 

    Foolish takeaway

    The Afterpay share price has continued to grow despite the entrance of payments giants like Paypal Holdings Inc (NASDAQ: PYPL), or the views of senior financial players. The company continues to sign strategic alliances like the one with Westpac, while continuing to report solid results quarter on quarter.

    Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

    *Returns as of 6/8/2020

    More reading

    Motley Fool contributor Daryl Mather has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Afterpay (ASX:APT) share price up 4% in today’s trading appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/38wyyEO

  • Here’s why the Ramelius (ASX:RMS) share price is zooming higher

    miniature rocket breaking out of golden egg representing rocketing share price

    The Ramelius Resources Limited (ASX: RMS) share price has been a strong performer on Monday.

    In afternoon trade the gold miner’s shares are up 4.5% to $2.33.

    Why is the Ramelius share price charging higher?

    There have been a couple of catalysts for today’s strong share price gains.

    The first is a jump in the gold price on Friday night which has given most gold miners a lift today.

    So much so, the S&P/ASX All Ordinaries Gold index is up a sizeable 1.6% at the time of writing even with investor risk appetite increasing.

    What else is driving the Ramelius share price higher?

    In addition to the above, a positive announcement by Ramelius this afternoon has supported its share price.

    That announcement reveals that the results of its Penny Feasibility Study (Mt Magnet) have been strong and led to the company’s board giving the go ahead to expedite the project’s development.

    The study found an all-in sustaining cost (AISC) of A$633 per ounce, down from previous estimates of A$703 per ounce.

    As a result of compelling financial outcomes from the Penny Feasibility Study, the company has also approved a decision-to-mine to bring the project into production in the June 2021 quarter. This is slightly earlier than contemplated by the prefeasibility study.

    Management commented: “The high grade Penny project will generate significant financial returns at the modelled gold price of A$2,300/oz and current spot prices of approximately A$2,650/oz. At an assumed price of A$2,650/oz, the project generates an AISC margin of just over A$2,000 per ounce.”

    Edna May, Western Australia.

    Furthermore, an updated mineral resource at Edna May has been completed successfully.

    According to the release, the study has led to a 22% mineral resource increase from previous estimates.

    Management notes that the option study for bulk underground versus narrow vein mining is progressing, and will also include consideration of Stage 3 open pit and potential interaction.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Here’s why the Ramelius (ASX:RMS) share price is zooming higher appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3nitBE7

  • Latest 3 “buy” recommendations from top brokers

    3 asx shares to buy depicted by man holding up hand with 3 fingers up

    The S&P/ASX 200 Index (Index:^AXJO) is surging higher and the good times are likely to roll on. Markets are embracing a Joe Biden US presidency and prospects of greater central bank stimulus.

    It’s hard to see what could sink the ongoing rally – barring an unexpected black swan event. This should clear the way for a decent Santa Rally.

    Here are the latest three ASX stocks that brokers are urging you to buy today.

    Buy Macquarie for rebound potential

    The Macquarie Group Ltd (ASX: MQG) share price is one to watch following its first half profit results.

    The bank’s interim dividend of $1.35 was around 8% below consensus and the slightly better than expected profit result was driven by the “lumpy” divisions in the bank.

    But Morgan Stanley isn’t perturbed and it reiterated its “overweight” recommendation on the Macquarie share price.

    “We think 1H21 was a low point for earnings,” said the broker.

    “The combination of a better outlook for gains on sale & performance fees, solid MIRA flows, and lower impairments should stabilise earnings in 2H21, with 30% recovery in FY22, in our view.”

    What’s more, Morgan Stanley reckons impairment losses at the bank has peaked with better than expected outcomes for most divisions.

    The broker’s 12-month price target on the stock is $148 a share.

    Well wrapped for Santa Rally

    Meanwhile, the Amcor CDI (ASX: AMC) share price is another to put on your watchlist following its quarterly results.

    The analysts at Macquarie repeated the “outperform” rating on the packaging group as they describe Amcor as an attractive, resilient and defensive business.

    “The US has been a strong point for most companies in Q3, and AMC was no exception, with North America flexibles vols up mid-single digit (vs low single digit in 2H20),” said the broker.

    “Rigids also saw improved momentum, with vols +4% vs +1% in 2H20, driven by improved sequential demand in the US convenience channel and likely pantry-filling (again) of Gatorade.”

    Despite these positives, the Amcor share price is trading at a discount to peers and its historical average.

    Amcor is priced at a 20% discount to the ASX 100 when the 10-year average is a 7% premium. Macquarie’s 12-month price target on Amcor is $17.85 a share.

    The good oil to fire up the NUF share price

    The embattled Nufarm Limited (ASX: NUF) share price could make a comeback with Citigroup reiterating its “buy” call on the stock.

    There is a close to 50% total return upside to the NUF share price based on the broker’s estimates. Earnings growth from the agri-business group’s omega-3 oil enriched canola seeds is a key driver for this bullish call.

    “While the initial earnings contribution should be small, we see omega-3 canola as a material long term earnings driver for Nufarm,” said Citi.

    “Based on our own bottom-up analysis of fish oil demand for the global aquaculture industry, we estimate a ~418kt pa demand deficit will emerge by 2028.”

    The new omega-3 products is estimated to be worth up to $1.57 a share for Nufarm and Citi’s 12-month price target on the stock is $5.30 a share.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor Brendon Lau owns shares of Macquarie Group Limited and Nufarm Limited. The Motley Fool Australia owns shares of and has recommended Amcor Limited and Macquarie Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Latest 3 “buy” recommendations from top brokers appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3piq5LN

  • 3 mid-cap ASX shares with recent price pullbacks

    3 asx shares to buy depicted by man holding up hand with 3 fingers up

    Below, I discuss three mid-cap companies that have performed strongly this year, but which have suffered minor pullbacks in their share prices during the past week due to various reasons.

    All of these 3 ASX shares announced strong results in 2020 and the first quarter of FY21. 

    FINEOS Corporation Holdings plc (ASX: FCL)

    Insurance software developer Fineos is having a great year, and that’s been reflected in its share price. At the time of writing, the Fineos share price has surged by 57%, year to date (YTD). However, the share price experienced a pullback last week, declining by 11%.

    Despite the challenges posed by the COVID-19 pandemic, Fineos has managed to achieve a number of milestones in 2020, including signing the largest insurance company in the United States and recently acquiring software company Limelight Health, Inc.

    The company also reported solid metrics in its FY20 results, with growth in revenues of close to 40%. The company also expects that it will continue its impressive run rate in FY21, forecasting revenue growth of 20%, underpinned by 30% growth in subscription revenues.

    Back in February, the company announced that it has signed up Prudential Insurance Company of America, the largest insurance company in the US – a breakthrough that the company says has opened the door to its foray into the much larger American insurance market.

    At the time of writing, Fineos is trading at $4.16 with a market cap of $1.25 billion.

    HUB24 Ltd (ASX: HUB)

    HUB24’s share price broke though a few all-time highs in 2020, on its way to achieving a 93% increase YTD. However, it steered off-course slightly in the past week, dropping by 6%.

    HUB24 Ltd (HUB, formerly Investorfirst Limited) is a fintech company that leverages technology to connect advisers and their clients through wealth management solutions. HUB24 is a fully-integrated solution for super, investment, pension, insurance and margin lending, used by advisers to serve their clients. The company first listed on the ASX in 2007.

    In its last performance update in September, HUB24 revealed that its strong results have continued in the first quarter of FY 2021. For the three months ended 30 September, the company reported a significant increase of 32% in its funds under administration (FUA) to $19 billion at the end of September.

    In late October, the company requested a trading halt on its shares whilst it launched a $60 million equity rising to fund stakes in three strategic investments – Xplore Wealth Ltd (ASX: XPL), the Portfolio Administration and Reporting Service (PARS), and a stake in Easton Investments Ltd (ASX: EAS).

    The company believes these transactions will strengthen its position as the leading provider of integrated platforms and data to its financial services clients. 

    At the time of writing, the HUB24 share price is trading at $21.5, commanding a market cap of $1.42 billion.

    Pushpay Holdings Ltd (ASX: PPH)

    Pushpay has had a very remarkable year, with its share price skyrocketing by 102% YTD at today’s levels. Like HUB24, this company is also a fintech player. It offers donor management tools to a niche market – religious organisations and non-profits. In addition, it sells the Church Community Builder software, a subscription-based church management platform that enables management of various church activities. Its revenue is almost derived entirely from the US. 

    In its FY21 results, the company reported an operating revenue increase of 53% to US$85.6 million. Pushpay said it expects to see continued revenue growth as the business executes on its strategy and gains further market share in the US faith sector. The company believes that as the world is fast moving toward a cashless society, donations will also move in that direction.

    The religious donation market is estimated to be around US$100 billion in the US, with Pushpay getting 10% of this slice. This potential has turned heads of some fund managers, with fundie Eley Griffiths announcing that it recently added Pushpal to its portfolio.

    As mentioned, Pushpal’s share price has risen by 102% this year, trading at $7.90 currently which brings its market cap to $2.2 billion. 

    Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

    *Returns as of 6/8/2020

    More reading

    Eddy Sunarto has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Hub24 Ltd and PUSHPAY FPO NZX. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends FINEOS Holdings plc. The Motley Fool Australia has recommended FINEOS Holdings plc, Hub24 Ltd, and PUSHPAY FPO NZX. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 mid-cap ASX shares with recent price pullbacks appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2IiCZZ7

  • Why the Noxopharm (ASX:NOX) share price surged 8% higher today

    beat the share market

    The Noxopharm Ltd (ASX: NOX) share price has started the week in a positive fashion.

    At one stage today the clinical-stage drug development company’s shares were up as much as 8% to 54 cents.

    The Noxopharm share price has since pulled back a touch but is still up 2% to 51 cents at the time of writing.

    Why did the Noxopharm share price surge higher?

    Investors were buying Noxopharm shares today after it announced that it has joined a pilot study (IONIC-1) to explore the ability of Veyonda to boost the effectiveness of Bristol Myers Squibb’s nivolumab (Opdivo) for the treatment of cancer.

    Veyonda is a second-generation immuno-oncology drug candidate based on selective inhibition in cancer cells of the pro-survival secondary messenger, sphingosine-1-phosphate (S1P).

    The company notes that the body uses a gradient of S1P levels (high to low) to move immune cells between blood and tissues. Cancers express high levels of S1P, reversing that gradient and thereby expelling immune cells from tumours.

    By inhibiting S1P in tumours, Veyonda is designed to restore a normal gradient, thereby allowing immune cells to repopulate tumours in a so-called COLD to HOT conversion.

    What is IONIC-1?

    Immune checkpoint inhibitors such as nivolumab have revolutionised the treatment of some cancers with what can be dramatic life-saving benefits. However, management notes that some patients have inherent resistance to immune checkpoint inhibitors.

    The IONIC-1 study will investigate whether Veyonda is able to overcome this resistance in patients with cancers such as breast, ovarian, prostate, and sarcoma cancers.

    Principal Investigator and eminent oncologist, Professor De Souza, commented: “I’m excited to be working with Noxopharm and Bristol Myers Squibb on this study. Checkpoint inhibitors have made a tremendous difference to some patients with advanced cancer and if we can increase the number of patients that respond through the addition of Veyonda to their treatment regimen, we will make a significant impact, not only to those individuals, but also on the oncology landscape.”

    The checkpoint inhibitor market, encompassing PD-1, PD-L1 and CTLA-4 inhibitors, is a multi-billion-dollar market which is experiencing rapid year on year growth. It is currently dominated by two major global pharmaceutical companies, one of which is Bristol Myers Squibb.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why the Noxopharm (ASX:NOX) share price surged 8% higher today appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/36gXNIP

  • Digital Wine Ventures (ASX: DW8) rockets 10% on record sales

    treasury wine shares

    The Digital Wine Ventures Ltd (ASX: DW8) share price jumped 10% on Monday after a record number of sales in October. Its shares are up more than 700% this year after a flurry of bullish sales announcements. 

    About Digital Wine Ventures 

    Digital Wine Ventures identifies and invests in early stage technology driven ventures that have the potential to disrupt and digitally transform segments within the global beverage market and support them by providing access to capital, expertise and share services. WINEDEPOT is the company’s coronership investment. 

    WINEDEPOT is a cloud-based software-as-a-service technology platform that empowers direct-to-market sales. It provides value to customers by removing layers of inefficiency in the supply chain. The company operates a network of strategically located deposits servicing key markets, supported by bulk storage centres. Its depots are combined with a software offering that provides customers with direct-to-trade marketplaces, order management systems and smart logistics solutions.  

    Company update 

    On Monday, the WINEDEPOT business shipped a total of 9,749 cases in October, up 34% on the total cases shipped in September. WINEDEPOT also processed another record number of orders in October at 5,817, up 23% on the previous record breaking month in September. 

    The WINEDEPOT platform also added 57 new brands to the platform including various Australian and New Zealand producers, craft spirit & beverage producers and wine distributors. 

    Poised for growth 

    Digital Wines is creating a springboard for growth for its WINEDEPOT business and goal to disrupt the global beverage market. The company’s quarterly update, announced on 27 October, points to the series financial, operational and acquisition actions taken by management to secure its future growth prospects. 

    On 14 October, it entered into an agreement to acquire Wine Delivery Australia Pty Ltd, a South Australia based fourth-party logistics provider servicing the wine industry to accelerate WINEDEPOT’s growth. 

    During the quarter, the company also successfully completed a $6 million capital raising to accelerate WINEDEPOT’s growth strategy through the launch of its marketplace and expansion of smart logistic business required to support the marketplace. 

    Furthermore, the company quadrupled its sales and market team with several new high profile executives joining the team. 

    The Digital Wines share price has retreated slightly from its intraday high, and is trading up 8.7% at the time of writing.

    Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

    *Returns as of 6/8/2020

    More reading

    Motley Fool contributor Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Digital Wine Ventures (ASX: DW8) rockets 10% on record sales appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3eFbxk7

  • Why the ANZ (ASX:ANZ) share price is underperforming on Monday

    ANZ Bank

    The S&P/ASX 200 Index (ASX: XJO) and the banking sector may be pushing higher on Monday, but the same cannot be said for the Australia and New Zealand Banking GrpLtd (ASX: ANZ) share price.

    In afternoon trade the banking giant’s shares are down almost 2.5% to $19.14.

    Why is the ANZ share price underperforming today?

    The underperformance of the ANZ share price on Monday has little to do with its business operations and a lot to do with its dividend.

    This is because this morning the bank’s shares traded ex-dividend for the final dividend it declared with its full year results at the end of last month.

    When a share trades ex-dividend, it means that it is now without the rights to a future dividend payment. Essentially, the seller of the share will receive the dividend and the buyer will get nothing.

    In light of this, a share price will generally decline in line with its dividend to reflect this.

    What is ANZ’s dividend?

    Last month ANZ declared a fully franked final dividend of 35 cents per share, down from 80 cents per share a year earlier.

    This dividend will now be paid to eligible shareholders in a touch over five weeks on December 16.

    What about the other banks?

    ANZ shares aren’t the only ones to trade ex-dividend this month.

    Next in line to go ex-dividend is the Westpac Banking Corp (ASX: WBC) share price on Wednesday for its 31 cents per share fully franked dividend. This will then be paid to eligible Westpac shareholders on 18 December.

    After which, a day later National Australia Bank Ltd (ASX: NAB) shares will trade without the rights to its final fully franked dividend of 30 cents per share. This dividend will be paid to eligible NAB shareholders on 10 December.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro owns shares of Westpac Banking. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why the ANZ (ASX:ANZ) share price is underperforming on Monday appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2Ibf5z4

  • Why the Immuron (ASX:IMC) share price is rocketing 18% higher today

    boy dressed in business suit with rocket wings attached looking skyward

    The Immuron Limited (ASX: IMC) share price is soaring today, up 18% in afternoon trading.

    This comes after the company announced positive results to one of its vaccines.

    Today’s gains put Immuron’s share price up 104% in 2020 at 26 cents per share, though that’s still well below the 86 cents per share Immuron briefly hit on 21 July. That spike followed a report that one of its flagship drugs, Travelan, could help treat respiratory issues in patients with COVID-19.

    Despite retracing since then, long-term investors likely won’t be complaining about the 104% gains in 2020 in a year that’s seen the All Ordinaries Index (ASX: XAO) fall by 6%.

    What does Immuron do?

    Immuron Limited is an Australian biopharmaceutical company. Its focus is the development and sale of oral immunotherapeutics to prevent and treat unmet medical needs. The company’s orally active polyclonal antibodies provide a targeted delivery inside the gastrointestinal tract so they do not cross into the bloodstream

    Immuron’s shares first began trading on the ASX in April 1999.

    What did Immuron announce to see its share price rocket 18% today?

    In this morning’s announcement to the ASX, Immuron revealed that the US Medical Research Center has confirmed its experimental vaccine produced “a robust immunological response in cows”.

    Immuron’s vaccine targets Campylobacter and Enterotoxigenic E.coli (ETEC). The company’s goal is to develop a multi-pathogen anti-diarrhoeal colostrum supplement to help protect against both afflictions, which are the main cause for infectious diarrhoea for people visiting developing countries.

    This is also a critical issue for the US military, whose personnel are often deployed to remote regions, and report that infectious diarrhoea is their most common illness.

    No surprise then, that the US Department of Defense (DoD) is interested in pursuing Immuron’s experimental vaccine. According to this morning’s release, PCI Clinical Services has been contracted to manufacture its drug product for the DoD to evaluate in clinical trials. Manufacturing is slated to start in November and be complete by the end of 2020.

    Two human phase II clinical trials are scheduled for 2021. The US Naval Medical Research Center plans to file a request with the US Food and Drug Administration (FDA) for an Investigational New Drug application in the first quarter of 2021.

    As these trials progress, Immuron’s share price will be one to watch.

    Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

    *Returns as of 6/8/2020

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why the Immuron (ASX:IMC) share price is rocketing 18% higher today appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/32oFj7U

  • Don’t fall in love with a charismatic CEO, says fundie

    Fund manager Damien Klassen

    Ask A Fund Manager

    The Motley Fool chats with fund managers so that you can get an insight into how the professionals think. In this edition, Nucleus Wealth head of investments Damien Klassen tells us how he picks the shares for his fund and why he’s holding onto a pile of cash.

     

    The Motley Fool: For Nucleus Wealth’s growth fund, what’s the philosophy?

    Damien Klassen: We have a big focus on quality and value. The way we think of stocks is that every stock’s got an inherent quality to it, and then a particular value. And it’s about finding the right cross section of those two. 

    For example, if we’re looking at a very high quality stock within our portfolio, then we’re actually happy to pay a little bit more for it. Whereas if we’re looking at, say, the average quality stock, then we want to be buying it really cheap. 

    The discipline for us is all about finding that right match between the quality and the value of the stock that we’re buying.

    One more overlay is, on the growth funds we then use… both quantitative modelling and macro outlook views to work out the right mix of whether we’re buying equities or whether we’re putting the money into bonds or cash.

    MF: So at the moment what’s the split between equities, bonds and cash?

    DK: Very much towards bonds and cash. We’re basically looking at valuations and we figure that we’ll have a better opportunity to buy it at cheaper prices. 

    So the last couple of months we’ve been winding back and just given the risks around, now’s more time to be cautious and we’ve managed to pick up some decent returns from bonds.

    We saw earlier on this week, the RBA cutting rates down to levels they said they’d never do. And we’ve had that view for a while that they would need to keep doing more – and we still have the view they need to keep doing more. So we don’t think all the returns have gone from that end of the market yet.

    COVID-19 crash 

    MF: Did you manage to buy a bit during the February-March dip?

    DK: We bought a little bit. The key thing we did was we got out of everything very early. So it was actually the end of January, early February that we cleared out completely.

    We’d been watching the coronavirus stats growing quite quickly. And we just figured that we’re reaching a point in the cycle that it was time to pull out.

    MF: There’s a viral video of you saying in January that the coronavirus would be a headwind.

    DK: Yeah. There’s an interview we did on the ABC where the stockbroker was saying, “No, it wasn’t going to be the next financial crisis”, and I was saying, “Look, I think it is going to be the next financial crisis.” 

    What it meant was we saved a lot of money for our clients from that decision and that, so we’ve been quite measured in terms of what we’ve been buying. 

    And we think that the market bounce back reached heights that we don’t think is justified. There’s certainly stocks out there that are fine, but in aggregate, we think the aggregate stocks that you can get, the risk return just doesn’t add up.

    Buying and selling 

    MF: What do you look at closely when considering buying a stock?

    DK: The first thing we do is any stock must fit into that quality value rank. We spent a lot of time trying to work out whether what we’ve got is true. What I mean by that is that it’s quite easy to create quantitative models that back-test very well in the past. The problem is getting models that are actually going to work going forward. 

    For every stock, you do need to go through and do a fundamental screen. So stocks that come up as being both very high quality and very cheap might seem like they’re going to be the greatest things ever, but almost always they’re value traps or they’ve got some fundamental problems. 

    It might be a healthcare stock that looks really great, but its patent is just about to expire in three years time or something like that, and there’s going to be a wave of competitors coming through. Or it might be a mine that’s finishing in five years. They’re making great profits now, everything looks great, but the profit’s going to run out.

    And so a lot of it is going through the fundamentals and not taking just a quantitative [view], but the qualitative as well.

    MF: What triggers you to sell a share?

    DK: Because we run this quite disciplined process in terms of quantitative measures, it actually puts the focus back on the analyst to justify things, because I think people have this natural tendency where you find a stock that’s quite cheap and the quality is just average. 

    It’s nothing special, nothing terrible, but it’s an average stock and it’s very cheap and people go and buy it. And next thing you know, the stock’s gone up a lot, say it’s doubled. And people start trying to convince themselves that actually, maybe this is a really high quality stock.

    It’s easy to fall in love with stocks from that perspective, and that’s where we use a quantitative process. Because the quantitative process doesn’t care about when you bought it or when you sold it. It’s basically just saying, no, this stock is expensive now, and the quality hasn’t changed and it’s up to the analysts to come back and justify the change or make changes to our outlook to keep it within the model. 

    We do have a lot more scope for the very high quality companies. We have scope for that to run a little bit further. So we can buy them when they’re average quality, average price. And they might run up to being a little bit expensive before we finally pull the trigger and say, “Okay, enough’s enough. It’s just too expensive at this point.”

    What’s coming up?

    MF: Where do you think the world is heading at the moment?

    DK: Back into more lockdowns is probably the obvious answer. 

    We’re in this weird tension where I think the coronavirus was treated as being a very short term problem by governments all around the world, and lots of stimulus was thrown at it: “We just need to get through this short two, three months shut down, and then everything will be back to normal”. 

    If we can just keep everything going the way it is then it’ll be fine, which if you don’t know how long it’s going to go for, that’s a fine assumption to make. But now we know it’s not, and we know the vaccines aren’t coming quickly. And when they do come, it’ll be question marks about how fast they get rolled out… So some of the measures to put in place at the start and not the right measures for this type of outcome. 

    For example, we put a lot of the stimulus was all front-loaded, and that is starting to fall off. Now we actually need stimulus to get people into new jobs because the old jobs – whether it be the number of waiters needed, people in the tourism sector or the number of airline hostesses we need – is a lot lower than what it used to be. We need to be finding those people new jobs. So the stimulus needs to be focused more about that, rather than trying to say, “Can we just maintain what we used to have?”

    The other part is that there were a lot of things put on in terms of stopping corporate bankruptcies and letting people go without paying their rent. Personal bankruptcies, we need to start letting these occur in a measured way, because what’s happening is the bad actors are going to start pulling down the good actors. 

    If you’ve got companies out there that should have gone broke six months ago, but didn’t, and they’re allowed to stay out there accruing more deaths… One supplier stops supplying to them because they won’t pay their bill. They switch to the next supplier and the next supplier and the next supplier, and these guys can’t take them to court because they’re not allowed to, and so these guys just keep racking up these bills.

    When they do go broke, now they can’t afford to pay their employees entitlements, and maybe they pulled down some of these suppliers who were overextended giving free stuff. So you’re starting to run into other problems. 

    And we’re waiting to see if the next round of stimulus is going to be as big as the last one. It doesn’t look like it’s going to be, and a divided house in the US isn’t going to help that. So we’re quite concerned about the economic outlook. For us it’s about trying to balance that with the extreme optimism we’re seeing in the stock market.

    Overrated and underrated shares

    MF: What’s your most underrated stock at the moment?

    DK: I’m going to put it into a category. It’s the value stocks which are underrated at the moment… Stocks that tend to be quite cheap, but there’s no obvious catalyst. 

    Quite often the story actually just isn’t that interesting within those stocks. I’ll use an example. There’s Intel Corporation (NASDAQ: INTC) – a supplier of computer chips – and their main competitor Advanced Micro Devices, Inc (NASDAQ: AMD), which recently came out with a much better chip. AMD is a lot smaller and more nimbler, and the share price has been on a tear. Whereas the Intel price has been going in the opposite direction.

    So two companies in the same sector with wildly different outlooks and I would certainly agree that AMD from a fundamental perspective looks way better. But if you look at last year’s earnings, Intel’s a little bit under 9 times last year’s earnings, whereas AMD’s on 90 times last year’s earnings. 

    So you’ve got to go, well, AMD is absolutely better. Is it 10 times better? 

    We look through that in a number of other different sectors. The names we come up with, quite frankly are quite boring. It might be things like HP or others that are just trading on price-to-earnings (P/E) ratios below 10, growth is looking actually quite anemic. And you’re not looking like you are going to get much performance, much earnings growth out of them. But at those rates, you’re actually getting a good yield. 

    They’re doing buybacks. As long as the capital is being managed, you just don’t know when it’s going to come good though, because it isn’t a sexy story. 

    It’s another thing when the market takes a bit of a tumble. A stock that’s on a 100 times PE has got a lot further to fall than a stock that’s on 7 or 8 times PE.

    MF: What do you think is the most overrated stock at the moment?

    DK: Certainly there’s some stocks in the tech sector that don’t deserve their premium. So we look through it and behind every bubble, there’s usually a grain of truth and there are stocks out there that we can look at within the tech sector we see why. 

    Tesla Inc (NASDAQ: TSLA)’s… probably one of the poster childs of very expensive, effectively not earning anything. It’s a story stock. So they make really nice cars, but is a stock 4 or 5 times better than what it was at the start of the year? 

    It’s pretty tough to come up with a reason why. But there’s a good story behind it, and everyone loves Elon Musk. Maybe not everyone, but there’s a large number of people who love him.

    MF: He has a personality cult going on, hasn’t he?

    DK: Exactly. We tend not to meet management for that reason. We’ll listen in to calls and we’ll run through the transcripts and all that sort of stuff, but we try not to get too close because you can fall in love with stories and magnetic founders.

    Looking back

    MF: Which stock are you most proud of from a past purchase?

    DK: Vestas Wind Systems A/S (CPH: VWS) is a stock which we bought a few years ago… It is the world’s biggest supplier of wind turbines. It’s a Danish company. We’re starting to tip it out now, because it is getting very expensive. 

    A lot of the green stocks have all been pushed up with the whole idea of, okay, Trump’s not going to be president anymore and we’ll have a Democrat president. Therefore possibly a Green New Deal can bid up the prices of these. 

    At the time (of purchase), Trump was in and pushing hard against these renewable energies. Our view was that the costs for renewable energy would reach a stage where they were compelling even without subsidies.

    So that was one we bought and rode that up. Now we’re starting to move out of that. We still like the company, still think it’s high quality, but it’s just the sector that’s flavour of the minute at the moment. 

    And we’d like to buy back in at lower prices.

    MF: Has COVID-19 changed or altered your investment methods at all?

    DK: In terms of the overall philosophy we have for trying to buy high quality stocks at the right price, no, it hasn’t. What it has changed dramatically in terms of what we’ve done in our quantitative models is it means we’ve completely down-weighted both last year’s earnings and the current year’s earnings. 

    Because what we’re looking at very much as a company is, where did we think this company can actually get back to? It’s not about what they’re going to deliver in 2020 or in 2021, because we know those are distorted periods. 

    It’s about trying to work out how much insight we really have into those later years… and also looking at historical (performance) and where do we think there’s a reasonable level for companies to get back to?

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Tesla. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Don’t fall in love with a charismatic CEO, says fundie appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3lfX29c

  • Synlait (ASX:SM1) share price 8% higher on land covenant settlement

    pouring glass of milk from glass milk bottle

    The Synlait Milk Ltd (ASX: SM1) share price was 8% higher today after the New Zealand-based dairy company settled its Pokeno land covenant legal dispute. The company has since paused trading, pending a further announcement.

    Pokeno land decision

    In February 2018, Synlait announced the conditional purchase of 28 hectares of land in Pokeno to establish its second nutritional powder manufacturing site.  

    In November 2018, the High Court removed covenants over the land that would hinder Synlait’s development. Synlait then took ownership of the land. On May 2019, the Court of Appeal overturned a previous High Court decision to remove historic covenants, which, if left in place, would hinder Synlait’s intention to develop the site. 

    In June 2019, Synlait filed an application for leave to appeal to the Supreme Court to have this decision overturned. 

    The company’s FY20 announcement back in October revealed that Synlait had made a reasonable settlement offer and was working towards one of two outcomes which it believed to be in the best interest of all – a reasonable settlement offer, or a court outcome. 

    The Pokeno site 

    Synlait’s Pokeno site is a newly constructed facility that only began production in late September 2019. The facility has the capacity to produce 45,000 metric tonnes of product and capable of producing a full suite of nutritional, formulated powders including infant-grade skim milk, whole milk and infant formula base powders. 

    Synlait share price higher on settlement agreement

    On Monday, the company announced that it had reached a settlement with New Zealand Industrial Park Ltd and Karl Ye regarding the historic land covenants at the company’s Pokeno site.

    Synlait CEO Leon Clement commented:

    Synlait and New Zealand Industrial Park are committed to work collaboratively for the benefit and integration of the Pokeno community and are pleased to have this behind us. We are also pleased to provide certainty for Synlait’s shareholders, customers, farmer suppliers and staff.

    Further details of the settlement agreement could not be disclosed due to confidentiality. However, the company does state that the settlement price was reasonable and not material to Synlait. 

    At the time of writing, Synlait shares are in a trading halt. Prior to this occurring, the Synlait share price had shot up by more than 8% on the news, trading for $5.54 per share.

    These Dividend Stocks Could Be Your Next Cash Kings (FREE REPORT)

    Motley Fool Australia’s Dividend experts recently released a brand-new FREE report revealing 3 dividend stocks with JUICY franked dividends that could keep paying you meaty dividends for years to come.

    Our team of investors think these 3 dividend stocks should be a ‘must consider’ for any savvy dividend investor. But more importantly, could potentially make Australian investors a heap of passive income.

    Don’t miss out! Simply click the link below to grab your free copy and discover these 3 high conviction stocks now.

    Returns As of 6th October 2020

    More reading

    Motley Fool contributor Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Synlait (ASX:SM1) share price 8% higher on land covenant settlement appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2Ijb62O